Reviewed by Vinsent Franke, MBA, AMFT, CADC-II, RA, Founder of iRely Recovery. Updated September 2026.
Intro
Psychedelic drugs offer a promise of insights, escape, and a spiritual awakening. For some, they deliver, but others end up in a cycle of blurred reality, collapsed relationships, and poor mental health. Whether it’s acid, mushrooms, ketamine, or a designer hallucinogen, it often starts with the ability to “expand the mind” with a trip.
At our Los Angeles psychedelic addiction treatment center, we can help you stop chasing your next high, trip, or out-of-body experience and build a life you don’t need to escape.
Key Points
- Hallucinogens alter perceptionAlso known as psychedelic drugs, they alter perception of self, time, and surroundings.
- Commonly misused psychedelicsPCP, LSD, psilocybin, ketamine, DMT, and MDMA are among the most commonly misused hallucinogens.
- Not physically addictive, still dangerousThough not physically addictive like opioids, hallucinogens cause hallucinogen use disorder with serious life consequences.
- HPPD can persist for yearsHallucinogen persisting perception disorder (HPPD) can cause visual disturbances lasting months or years after stopping.
- Evidence-based care in Los AngelesiRely Recovery offers evidence-based psychedelic addiction treatment at ASAM Level 3.5 residential facilities.
But then the trips keep coming — along with the fallout. What starts as a way to expand your mind can quietly become a pattern you can’t step out of.
What Are Hallucinogens?
Hallucinogens are a broad category of drugs that alter perceptions, causing sensations, visions, or beliefs that aren’t real.[1] LSD, psilocybin, mescaline, and ketamine are examples of hallucinogenic drugs.
Hallucinogens can refer to many different drugs, often known as “psychedelic drugs.” Both classic hallucinogens and dissociative drugs fall in this category, with only subtle differences between them. They’re capable of making you see, hear, and feel things that aren’t real, but dissociative drugs can elicit dissociative experiences – or an out-of-body experience in which you feel disconnected from your mind, body, or surroundings.[2]
How Hallucinogens Work in the Brain
Classic psychedelics such as LSD and psilocybin primarily act on serotonin 5-HT2A receptors, disrupting normal sensory processing and producing altered states of consciousness. Dissociative drugs like ketamine and PCP block NMDA glutamate receptors, causing feelings of detachment and, in high doses, full dissociation. MDMA triggers massive releases of serotonin, dopamine, and norepinephrine, producing its characteristic empathogenic and mild hallucinogenic effects.
Why “Natural” Does Not Mean Safe: Psilocybin and mescaline are plant-derived. LSD is synthesized from a natural fungus. Yet all carry significant psychological risks with repeated use, and the perception of safety based on natural origin is one of the primary reasons hallucinogen use disorder goes unrecognized and untreated.
Key Statistics and Facts About Hallucinogen Use
5.7 Million Americans
Aged 12 or older reported past-year hallucinogen use, per SAMHSA’s 2022 National Survey on Drug Use and Health.[19]
A Clinical Diagnosis
Hallucinogen use disorder is classified in the DSM-5 as “other hallucinogen use disorder,” not just recreational overuse.[20]
4.2% Develop HPPD
An estimated 4.2% of people who have used LSD develop HPPD, with symptoms persisting months to years after last use.[21]
Highest Addiction Potential
Ketamine and MDMA carry the highest addiction potential among psychedelics due to their dopaminergic activity, per NIDA research.[22]
Ages 18 to 25 Highest Risk
Young adults have the highest prevalence of hallucinogen use, with LSD and psilocybin the most common substances in this group.
Rising ER Visits
Emergency department visits involving hallucinogens increased significantly with the rise of festival culture and designer psychedelics from 2015 to 2023.
Hundreds Helped in LA
iRely Recovery has supported hundreds of Los Angeles residents in recovering from hallucinogen use disorder and co-occurring mental health conditions.
Why Choose iRely Recovery for Psychedelic Addiction Treatment in Los Angeles?
iRely Recovery operates two ASAM Level 3.5 residential facilities in the Sherwood Forest neighborhood of Los Angeles: Greenwood Manor (17524 Napa St, Sherwood Forest, CA 91325) and Willow View (17526 Napa St, Sherwood Forest, CA 91325). Our clinical team has deep expertise in the unique profile of psychedelic and hallucinogen use disorders – particularly the co-occurring anxiety, depersonalization, HPPD, and trauma that characterize this patient population.
Psychedelic-Specific Clinical Expertise
Assessment and treatment of HPPD, depersonalization disorder, and hallucinogen-induced psychosis.
Dual Diagnosis Leadership
More than 70% of patients with hallucinogen use disorder have a co-occurring depression, anxiety, or PTSD; we treat both simultaneously with our dual diagnosis treatment program.
13 Evidence-Based Modalities
From CBT and DBT to somatic experiencing, adventure therapy, and trauma-informed care.
24/7 Medical Supervision
ASAM Level 3.5 residential care with psychiatric support and clinical oversight around the clock.
No-Judgment Environment
We understand the spiritual and exploratory motivations behind psychedelic use and provide care without shame.
Aftercare Coordination
Discharge planning from day one; connections to PHP, IOP, sober living, and outpatient support across Los Angeles.
Clinical Reality: Hallucinogen use disorder is frequently missed in general addiction treatment programs that focus primarily on opioid or alcohol withdrawal. Our clinicians are specifically trained in psychedelic presentations.
Types of Hallucinogens and Psychedelic Drugs
Though hallucinogenic and psychedelic drugs have broad similarities in their effects, there are some important distinctions between them:
Lysergic Acid Diethylamide (LSD)
Also known as acid, LSD is hallucinogenic and known to warp reality and alter serotonin levels long after the trip ends, leading to unpredictable effects. LSD trips can last 8 to 12 hours; bad trips and HPPD are significant clinical risks.
Psilocybin
Commonly known as “magic mushrooms,” psilocybin is often consumed raw or dried to induce sensory distortion or hallucinations that can range from comforting or spiritual to terrifying. Increasing research into therapeutic use does not eliminate real psychological risks with uncontrolled use.
Phencyclidine (PCP)
Also known as “angel dust,” PCP is a synthetic drug that alters the body’s pain response and induces a high, but it can cause extreme aggression. PCP has the highest addiction potential among classic hallucinogens and is classified separately under DSM-5.
N,N-Dimethyltryptamine (DMT)
A serotonergic hallucinogen, DMT interacts with serotonin receptors in the brain to produce potent psychedelic effects. Often used for ritual purposes and shamanic practices, repeated use can trigger derealization. DMT is sometimes smoked or used in the form of ayahuasca, a ceremonial brew.
Ketamine
Known as “special K,” ketamine is used as a party drug or date-rape drug to induce a feeling of detachment. As an NMDA antagonist, ketamine carries a high addiction risk; compulsive use causes “K-holes,” bladder damage, and severe dissociative episodes.
Mescaline or Peyote
Peyote, which contains mescaline, comes from a small cactus native to the Southwestern U.S. and northern Mexico. Used for ritual purposes and as a recreational drug to induce hallucinogenic effects. Mescaline trips last 8 to 12 hours and can produce intense visual and emotional experiences.
Dextromethorphan (DXM)
A common cough suppressant, DXM is an easily accessible drug that can cause hallucinations at high doses. Available OTC in over 120 products, DXM misuse is most common among teenagers and young adults.
3,4-Methylenedioxymethamphetamine (MDMA)
Commonly known as ecstasy or molly, MDMA is a synthetic party drug that can increase empathy and awareness, though it has fewer hallucinatory effects than other psychedelics. It acts strongly on dopamine and serotonin systems, producing significant addiction risk and neurotoxicity with heavy use.
Hallucinogen Addiction and Abuse
The research is mixed on whether hallucinogens and psychedelics are addictive. The compulsive use of psychedelics is more psychological than physical, but it can still cause similar problems in daily life. Just because you’re not chasing a chemical dependency doesn’t mean you’re not still looking to escape – and that’s what makes it dangerous.
Hallucinogen addiction is classified as an “other hallucinogen use disorder” in the DSM-5. The criteria for a hallucinogen use disorder include:
- Taking hallucinogens in larger amounts or over longer periods than intended
- A persistent desire or unsuccessful efforts to cut down or control hallucinogen use
- Spending a lot of time getting, using, or recovering from hallucinogens
- Craving hallucinogens
- Failing to fulfill responsibilities at work, home, or school because of hallucinogen use
- Giving up important recreational activities because of hallucinogen use
- Using hallucinogens in situations that may be physically dangerous
- Continuing hallucinogen use despite knowing the problems it causes
Why Psychological Addiction Is Still Serious: The absence of physical withdrawal symptoms leads many people – and even some clinicians – to minimize hallucinogen use disorder. But psychological dependence can be equally disabling. Patients at iRely Recovery describe an inability to enjoy sober life, persistent cravings for altered states, and a progressive narrowing of identity around psychedelic use. These are clinical presentations that require professional treatment.
Hallucinogen Use Disorder vs. Recreational Use: The distinguishing factor is impairment. When psychedelic use begins to affect work, relationships, mental health, or physical safety, it meets the clinical threshold for a use disorder regardless of whether physical dependence is present.
Who We Treat at iRely Recovery
Festival and Concert Culture Participants
MDMA, LSD, and psilocybin use common in electronic music communities that has escalated from occasional to compulsive.
Spiritual Seekers and Wellness Culture Participants
People who began using ayahuasca, psilocybin, or DMT in ceremonial contexts and have developed psychological dependence.
Individuals with HPPD or Persistent Psychosis
Those experiencing flashbacks, visual snow, or derealization months or years after stopping psychedelic use.
Young Adults and College Students
Ages 18 to 25 represent the highest-risk demographic for LSD and psilocybin use disorder.
Dual Diagnosis Patients
Those self-medicating depression, PTSD, or anxiety with psychedelics who need integrated mental health and addiction treatment.
Ketamine Users
People who developed ketamine dependence from recreational use or diverted clinical use, including bladder and dissociation complications.
Working Professionals
Microdosing that has escalated, or weekend use that increasingly bleeds into the work week.
Hallucinogen Side Effects and Risks
Though these drugs have been viewed as safe because they’re “natural” and “therapeutic,” psychedelic overuse can mess with your brain, your body, and your future. After use, psychedelics can cause nausea, increased heart rate, agitation, and altered senses. Some of these side effects subside after the trip ends, but others can persist for weeks or months.
Psychedelics don’t just amplify positive emotions. They amplify everything. If the trip goes sour, it can cause you to go into a panic or feel like you’re losing your mind. That anxiety may not go away once you come out of it. Depersonalization and derealization can also occur, which causes you to feel like you’re watching “from the outside” of your life, numb, detached, and unsure of what’s real and what’s not. For some people, the crash after the trip – as the brain’s serotonin levels deplete – can cause significant depression and hopelessness.
Hallucinogen Persisting Perception Disorder (HPPD): One of the most serious long-term consequences of psychedelic use is HPPD. Patients experience persistent visual disturbances including afterimages, visual trails, geometric patterns, or halos around objects – even when completely sober. These symptoms can last for months or years. HPPD is not a “flashback” but a neurological condition that significantly impairs quality of life. At iRely Recovery, our clinical team specifically assesses for HPPD at intake and incorporates HPPD-informed care into treatment planning.
Cardiovascular and Neurological Risks:
- LSD and psilocybin: Elevated heart rate, blood pressure, dilated pupils; rare cases of serotonin syndrome when combined with SSRIs
- MDMA: Hyperthermia, dehydration, hyponatremia (dangerous low sodium from overdrinking water), serotonin neurotoxicity with heavy use
- Ketamine: Bladder and urinary tract damage (ketamine cystopathy) with chronic use; severe cognitive impairment
- PCP: Extreme aggression, seizures, respiratory arrest at high doses; high overdose risk
Treatment for Hallucinogen Use Disorder in Los Angeles
Hallucinogen addiction is mostly psychological, so the focus of treatment at iRely Recovery is on identifying the underlying causes of hallucinogen use and learning how to stay grounded in the present. Here are some of the treatment modalities we use:
Individual Therapy
One-on-one sessions dive deep into your patterns, stress, pain, and potential to find out why you want to escape or enhance reality.
Family Therapy
Hallucinogen abuse strains even the closest bonds. Family therapy brings loved ones into the healing process to rebuild trust and set boundaries that support long-term recovery.
Group Therapy
Connects you with others who are fighting the same fight, sharing real stories, engaging in honest conversations, and holding each other accountable to grow and connect.
Recovery-Oriented Treatment
Recovery from addiction is more than treating symptoms. Our recovery-oriented care focuses on identity, meaning, and purpose to help you feel whole without a good trip.
Cognitive Behavioral Therapy (CBT)
Breaks the cycle of distorted thinking and compulsive behavior to challenge the mental shortcuts that lead you back to drugs.
Dialectical Behavioral Therapy (DBT)
Hallucinogens are often used to escape emotional chaos, but DBT teaches emotional control, distress tolerance, impulse management, and the power of staying present.
Acceptance and Commitment Therapy (ACT)
Helps you face uncomfortable emotions and commit to actions that align with your values, rather than giving in to urges.
Somatic Experiencing Therapy
Trauma hides in the body. Somatic therapy helps you release physical tension and restore nervous system balance without the need for substances to “feel normal.”
Adventure Therapy
Uses real-world experiences in nature to reconnect you with your body, build confidence, and find joy in simplicity.
Trauma-Informed Care
Some people use psychedelics to cope with trauma. We ensure that your treatment is based on safety, choice, and empowerment, rather than re-traumatization.
Experiential Therapy
Art, role-playing, music, and movement therapy can unlock emotions and insights that words alone can’t reach.
Mindfulness-Based Therapy
Teaches awareness, presence, and peace without requiring you to alter your mind to achieve that state.
Motivational Interviewing (MI)
Still unsure if you’re ready to quit for good? MI meets you where you are to unpack your ambivalence and build authentic motivation from the inside out.
Admissions Process at iRely Recovery
Our admissions team is available 24/7 at (818) 262-3537 or (818) 698-2961. Getting started takes minutes.
Step 1: Free Confidential Assessment
A licensed clinician reviews your psychedelic use history, mental health background, and treatment needs.
Step 2: Insurance Verification
We verify your benefits within hours and explain your out-of-pocket costs transparently.
Step 3: Personalized Treatment Plan
Your clinical team designs a plan covering residential detox support, therapy modalities, and aftercare.
Step 4: Same-Day or Next-Day Admission
Most patients are admitted within 24 hours of first contact.
Step 5: Arrive and Begin
Welcome to our Sherwood Forest campus – intake, orientation, and first clinical session within hours of arrival.
Hallucinogen Withdrawal and Psychological Recovery Timeline
Important: Unlike opioids or benzodiazepines, hallucinogens do not cause significant physical withdrawal. The recovery challenge is primarily psychological – restoring serotonin regulation, emotional stability, and the ability to experience life without substance-altered perception.
Psychological Withdrawal Symptoms (Vary by Substance):
- LSD / Psilocybin: Depression, anhedonia, anxiety, and sensory hypersensitivity during the days following cessation; HPPD may persist independently
- MDMA: “Suicide Tuesday” – severe serotonin depletion producing depression and exhaustion 1 to 3 days after use; may last 1 to 2 weeks after heavy use
- Ketamine: Cravings, anxiety, insomnia, cognitive fog; in heavy users, physical withdrawal may include sweating and tremors
- PCP: Elevated anxiety, agitation, depression; severe cases may include psychosis lasting weeks
| Phase | What Happens |
|---|---|
| Days 1 to 7 | Acute psychological stabilization; medical monitoring, psychiatric support, initial therapy sessions |
| Weeks 2 to 4 | Serotonin system begins restoring; mood stabilizes; HPPD symptoms are assessed and addressed |
| Months 1 to 3 | Deeper therapeutic work on trauma, identity, and triggers; relapse prevention skills built |
| Months 3 to 6 | Sustained engagement with aftercare; rebuilding life structure and relationships |
Aftercare and Relapse Prevention in Los Angeles
Recovery from hallucinogen use disorder requires sustained support beyond residential treatment. iRely Recovery builds a comprehensive aftercare plan before every patient leaves our Los Angeles program.
Key Fact: Patients who engage in structured aftercare for at least 90 days following residential treatment show significantly higher rates of sustained recovery. We treat aftercare as part of the core treatment contract, not an optional add-on.
Aftercare Services We Coordinate:
- Partial Hospitalization Program (PHP): 5 to 6 hours of structured daily programming for patients stepping down from residential care
- Intensive Outpatient Program (IOP): 3 hours per day, 3 to 5 days per week; allows return to work or school while maintaining support
- Sober Living Referrals: We partner with vetted sober-living homes throughout Los Angeles County and the San Fernando Valley
- Alumni Program: Monthly events, peer mentorship, and ongoing alumni check-ins to sustain community connection
- Psychiatric Medication Management: Warm handoffs to outpatient psychiatrists for patients needing ongoing medication support for HPPD, depression, or anxiety
- SMART Recovery and 12-Step: We connect patients to Los Angeles-area meetings tailored to their preferences and recovery approach, with aftercare programs designed around each individual.
Psychedelic-Specific Relapse Prevention:
- Identifying high-risk situations: festivals, social circles, and environmental triggers linked to psychedelic use
- Managing HPPD triggers that may increase cravings for the perceived “normalizing” effect of redosing
- Building a sober identity that does not depend on altered states for meaning, creativity, or spiritual connection
- Developing a personal emergency action plan for psychedelic cravings and mental health crises
LSD Addiction Treatment in Los Angeles at iRely Recovery
LSD (acid) addiction, while primarily psychological, is a recognized clinical condition that disrupts serotonin function, blurs the line between reality and perception, and progressively narrows life around the next trip. At iRely Recovery in Los Angeles, we specialize in LSD use disorder treatment within our residential program.
Clinical Note: LSD does not cause physical dependence in the opioid sense, but the psychological pull of altered perception – particularly in people using LSD to escape depression, anxiety, or trauma – can be as powerful as any chemical dependency.
LSD addiction treatment at iRely Recovery includes:
- Psychiatric evaluation for HPPD, depersonalization disorder, and LSD-triggered psychosis
- EMDR and trauma-focused therapy addressing the underlying experiences that drive repeated LSD use
- CBT to challenge the belief that LSD is necessary for creativity, insight, or emotional access
- Mindfulness-based therapy to cultivate expanded awareness without substance use
- Aftercare coordination with Los Angeles outpatient programs specializing in psychedelic recovery
If you or a family member is struggling with LSD addiction in Los Angeles, call iRely Recovery at (818) 262-3537 for a free confidential assessment.
Psilocybin and MDMA Addiction Treatment in Los Angeles
Psilocybin (Magic Mushroom) Addiction Treatment
Despite the growing narrative around psilocybin’s therapeutic potential, uncontrolled misuse causes real harm. Frequent psilocybin use disrupts serotonin signaling, triggers persistent anxiety and depersonalization, and in vulnerable individuals, can precipitate psychosis. iRely Recovery’s treatment for psilocybin use disorder focuses on restoring serotonin balance through structured therapy, psychiatric support, and rebuilding the capacity for unassisted emotional regulation.
MDMA (Ecstasy / Molly) Addiction Treatment
MDMA carries the highest addiction risk among commonly used psychedelics because of its dopaminergic mechanism. Regular use depletes serotonin and dopamine stores, producing severe post-use depression and an escalating need for the drug to feel normal. MDMA-related neurotoxicity has been documented in heavy users, including long-term impairments in memory and mood regulation. iRely Recovery treats MDMA use disorder with dual-diagnosis psychiatric support, group process groups focused on emotional regulation, and targeted relapse prevention for club and festival culture triggers.
Ready to Build a Life You Don’t Need to Escape?
Hallucinogen use disorder is a real, treatable condition. You don’t have to choose between your inner world and a functioning life.
Call or Text: (818) 262-3537 | (818) 698-2961
Greenwood Manor: 17524 Napa St, Sherwood Forest, CA 91325
Willow View: 17526 Napa St, Sherwood Forest, CA 91325
Frequently Asked Questions About Hallucinogen and Psychedelic Addiction
What Are Hallucinogens’ Long-Term Effects?
Chronic hallucinogen use can cause hallucinogen persisting perception disorder (HPPD), depersonalization, anxiety, depression, memory problems, and emotional instability. Some people experience lasting psychosis, especially with frequent high-dose use. Ketamine causes bladder damage and cognitive impairment with chronic use, and MDMA is associated with serotonin neurotoxicity in heavy users.
Are Psychedelic and Dissociative Drugs Safe?
No, psychedelic and dissociative drugs are not safe for uncontrolled use. While some psychedelics are under clinical investigation in supervised settings, recreational misuse – especially combined with other substances – is psychologically dangerous. Dissociative drugs like ketamine and DXM carry a high risk of addiction, bladder damage, cognitive decline, and dissociative episodes.
Do Hallucinogens Have Withdrawal Symptoms?
Hallucinogens typically do not cause physical withdrawal like opioids or benzodiazepines. However, psychological withdrawal symptoms including depression, anxiety, cravings, restlessness, and insomnia occur with regular use. MDMA withdrawal produces severe serotonin depletion causing depression in the days following use. PCP and ketamine may produce more significant withdrawal symptoms including agitation and tremors.
What Is Hallucinogen Use Disorder?
Hallucinogen use disorder is a clinical diagnosis in the DSM-5 characterized by compulsive psychedelic use that causes significant impairment in daily life, relationships, or health. Key signs include using more than intended, unsuccessful attempts to stop, spending significant time obtaining or recovering from use, and continuing despite known harm. It does not require physical dependence to qualify as a diagnosable disorder.
What Is HPPD and How Is It Treated?
Hallucinogen persisting perception disorder (HPPD) is a neurological condition causing ongoing visual disturbances – afterimages, visual snow, trails, and halos – that persist after stopping psychedelic use. It affects an estimated 4.2% of LSD users. Treatment includes psychiatric evaluation, psychotherapy, and in some cases medication. iRely Recovery specifically assesses for and addresses HPPD in our residential treatment program.
What Is the Best Treatment for Hallucinogen Addiction?
Evidence-based psychotherapy is the foundation of hallucinogen addiction treatment, since the dependence is primarily psychological. At iRely Recovery, we use CBT, DBT, ACT, trauma-informed care, somatic therapy, and mindfulness-based approaches within an ASAM Level 3.5 residential setting. Dual-diagnosis psychiatric care is integrated for patients with co-occurring mental health conditions.
Can You Become Addicted to Psilocybin?
Psilocybin (magic mushrooms) has lower addiction potential than many drugs, but hallucinogen use disorder involving psilocybin does occur. Compulsive use, unsuccessful attempts to stop, and significant impairment in daily life are the clinical markers. The growing cultural narrative around psilocybin’s therapeutic benefits sometimes obscures the real risks of uncontrolled misuse.
Is MDMA or Ecstasy Addictive?
Yes. MDMA carries significant addiction risk due to its strong effects on dopamine and serotonin systems. Regular use leads to serotonin depletion, tolerance requiring higher doses to achieve the same effect, and severe depression between uses. MDMA-related neurotoxicity is documented in heavy users. iRely Recovery treats MDMA use disorder as part of our hallucinogen addiction program in Los Angeles.
How Long Does Psychedelic Addiction Treatment Take?
Residential treatment at iRely Recovery typically lasts 28 to 90 days, depending on the severity of use, co-occurring mental health conditions, and individual clinical need. Following residential care, most patients continue with PHP or IOP for 30 to 90 additional days, followed by ongoing outpatient support. The full continuum of care generally spans 6 to 12 months for lasting recovery.
Is There a Psychedelic Rehab Near Me in Los Angeles?
Yes. iRely Recovery operates two ASAM Level 3.5 residential facilities in the Sherwood Forest neighborhood of Los Angeles (17524 and 17526 Napa St, CA 91325). We serve patients from across Los Angeles County, the San Fernando Valley, and Southern California. Call (818) 262-3537 for a free confidential assessment and same-day or next-day admission.
What Is Hallucinogen Use Disorder Treatment Like for Young Adults?
Young adults aged 18 to 25 have the highest prevalence of hallucinogen use disorder. Treatment at iRely Recovery for this age group emphasizes identity and purpose work (building a life that does not center on substances), peer-group therapy, family involvement where appropriate, and addressing the anxiety or depression that frequently underlie early-onset psychedelic use.
Can Ketamine Addiction Be Treated at iRely Recovery?
Yes. Ketamine addiction is treated within our hallucinogen and dissociative drug program. Ketamine dependence requires specific attention to bladder health complications, cognitive recovery, and the dissociative symptoms that persist after stopping use. Our clinical team is trained in ketamine-specific presentations including k-hole episodes and ketamine cystopathy.
Does Hallucinogen Treatment Require Medical Detox?
Physical detox for classic psychedelics like LSD and psilocybin is generally not medically necessary because physical withdrawal is minimal. However, MDMA, PCP, and ketamine may require medical monitoring during the cessation period. iRely Recovery’s ASAM Level 3.5 program provides medical supervision for all patients through the stabilization phase regardless of substance, ensuring safety and comfort.
What Co-Occurring Disorders Are Common With Hallucinogen Addiction?
More than 70% of patients with hallucinogen use disorder at iRely Recovery have a co-occurring mental health condition. The most common include anxiety disorders, depression, PTSD, HPPD, depersonalization disorder, and ADHD. Undiagnosed mental health conditions frequently drive initial psychedelic use as self-medication, making integrated dual-diagnosis treatment essential.
How Do I Get Started With Hallucinogen Addiction Treatment at iRely Recovery?
Call or text (818) 262-3537 or (818) 698-2961 at any time – our admissions coordinators are available 24 hours a day, 7 days a week. We will complete a free confidential clinical assessment, verify your insurance benefits, and schedule your admission, typically within 24 hours. No referral from a doctor is required to contact us.
Sources
[1] 20144 hallucinogens. CAMH. (n.d.). https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/hallucinogens
[2] Raj, P., Rauniyar, S., & Sapkale, B. (2023, November 13). Psychedelic drugs or hallucinogens: Exploring their medicinal potential. Cureus. https://pmc.ncbi.nlm.nih.gov/articles/PMC10716812/
[3] Hwang, K. A. J. (2023, July 10). Lysergic acid diethylamide (LSD) (archived). StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK482407/
[4] GoodRx. (n.d.-a). Psilocybin (magic mushrooms): Side effects, benefits, risks. GoodRx. https://www.goodrx.com/health-topic/psychedelics/psilocybin-magic-mushrooms
[5] U.S. National Library of Medicine. (n.d.). Substance use – phencyclidine (PCP): Medlineplus medical encyclopedia. MedlinePlus. https://medlineplus.gov/ency/patientinstructions/000797.htm
[6] Carbonaro, T. M., & Gatch, M. B. (2016, September). Neuropharmacology of N,N-dimethyltryptamine. Brain research bulletin. https://pmc.ncbi.nlm.nih.gov/articles/PMC5048497/#S1title
[7] Rosenbaum, S. B. (2024, January 30). Ketamine. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK470357/
[8] Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2022, March). The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of psychopharmacology (Oxford, England). https://pmc.ncbi.nlm.nih.gov/articles/PMC8902264/#section5-02698811211013583title
[9] Martinak, B., Bolis, R. A., Black, J. R., Fargason, R. E., & Birur, B. (2017, September 15). Dextromethorphan in cough syrup: The poor man’s psychosis. Psychopharmacology bulletin. https://pmc.ncbi.nlm.nih.gov/articles/PMC5601090/
[10] MDMA (Ecstasy/Molly): Effects, hazards & extent of use. Drugs.com. (n.d.-c). https://www.drugs.com/illicit/mdma.html
[11] Bogenschutz, M. P., Bouso, J. C., Brady, K. T., Bruhn, J. G., Danforth, A. L., Dubois, S., Felitti, V. J., Gandek, B., Greenfield, S. F., Hallock, R. M., Hasin, D. S., Heim, C., … Goldstein, R. (2018, September 16). Epidemiology of hallucinogen use in the U.S. results from the national epidemiologic survey on alcohol and related conditions III. Addictive Behaviors. https://www.sciencedirect.com/science/article/abs/pii/S0306460318305355?via%3Dihub#preview-section-snippets
[12] Wu, L.-T., Ringwalt, C. L., Mannelli, P., & Patkar, A. A. (2008). Hallucinogen use disorders among adult users of MDMA and other hallucinogens. The American journal on addictions. https://pmc.ncbi.nlm.nih.gov/articles/PMC2648386/
[13] Other hallucinogen (LSD, MDMA) use disorder. PsychDB. (2021, March 29). https://www.psychdb.com/addictions/hallucinogens/3-other-use-disorder
[14] U.S. Department of Health and Human Services. (2025, April 25). Psychedelic and dissociative drugs. National Institutes of Health. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs#mental-illness
[15] Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., Luke, D., Michelle, K., & Prideaux, E. (2023, October 24). Extended difficulties following the use of psychedelic drugs: A mixed methods study. PloS one. https://pmc.ncbi.nlm.nih.gov/articles/PMC10597511/
[16] Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M. C., Lorusso, M., di Giannantonio, M., & Lerner, A. G. (2018, March 16). Hallucinogen persisting perception disorder: Etiology, clinical features, and therapeutic perspectives. Brain sciences. https://pmc.ncbi.nlm.nih.gov/articles/PMC5870365/
[17] U.S. Department of Health and Human Services. (2025, April 25). Psychedelic and dissociative drugs. National Institutes of Health. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs#mental-illness
[18] 20144 hallucinogens. CAMH. (n.d.). https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/hallucinogens
[19] Substance Abuse and Mental Health Services Administration. (2023). 2022 National Survey on Drug Use and Health (NSDUH). https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report
[20] American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Other Hallucinogen Use Disorder criteria.
[21] Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M. C., Lorusso, M., di Giannantonio, M., & Lerner, A. G. (2018, March 16). Hallucinogen persisting perception disorder: Etiology, clinical features, and therapeutic perspectives. Brain sciences. https://pmc.ncbi.nlm.nih.gov/articles/PMC5870365/
[22] National Institute on Drug Abuse (NIDA). Psychedelic and Dissociative Drugs research topic. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs
